Cargando…

Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab

Folliculitis decalvans (FD) is a rare idiopathic primary cicatricial alopecia which leads to permanent destruction of hair follicular stem cell. Staphylococcus aureus as well as autoimmunity has been implicated in the pathogenesis. Treatment options include topical antiseptics, topical and systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhameedy, Meshal M, Alsantali, Adel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984048/
https://www.ncbi.nlm.nih.gov/pubmed/32030059
http://dx.doi.org/10.4103/ijt.ijt_92_19
_version_ 1783491599214313472
author Alhameedy, Meshal M
Alsantali, Adel M
author_facet Alhameedy, Meshal M
Alsantali, Adel M
author_sort Alhameedy, Meshal M
collection PubMed
description Folliculitis decalvans (FD) is a rare idiopathic primary cicatricial alopecia which leads to permanent destruction of hair follicular stem cell. Staphylococcus aureus as well as autoimmunity has been implicated in the pathogenesis. Treatment options include topical antiseptics, topical and systemic corticosteroids, systemic antibiotics, isotretinoin, dapsone, hydroxychloroquine, and immunomodulators. We present the therapy-recalcitrant case of FD which is controlled successfully by subcutaneous injections of Adalimumab (Humira(®)) with no serious adverse events throughout the treatment.
format Online
Article
Text
id pubmed-6984048
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-69840482020-02-06 Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab Alhameedy, Meshal M Alsantali, Adel M Int J Trichology Case Report Folliculitis decalvans (FD) is a rare idiopathic primary cicatricial alopecia which leads to permanent destruction of hair follicular stem cell. Staphylococcus aureus as well as autoimmunity has been implicated in the pathogenesis. Treatment options include topical antiseptics, topical and systemic corticosteroids, systemic antibiotics, isotretinoin, dapsone, hydroxychloroquine, and immunomodulators. We present the therapy-recalcitrant case of FD which is controlled successfully by subcutaneous injections of Adalimumab (Humira(®)) with no serious adverse events throughout the treatment. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6984048/ /pubmed/32030059 http://dx.doi.org/10.4103/ijt.ijt_92_19 Text en Copyright: © 2020 International Journal of Trichology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Alhameedy, Meshal M
Alsantali, Adel M
Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab
title Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab
title_full Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab
title_fullStr Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab
title_full_unstemmed Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab
title_short Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab
title_sort therapy-recalcitrant folliculitis decalvans controlled successfully with adalimumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984048/
https://www.ncbi.nlm.nih.gov/pubmed/32030059
http://dx.doi.org/10.4103/ijt.ijt_92_19
work_keys_str_mv AT alhameedymeshalm therapyrecalcitrantfolliculitisdecalvanscontrolledsuccessfullywithadalimumab
AT alsantaliadelm therapyrecalcitrantfolliculitisdecalvanscontrolledsuccessfullywithadalimumab